

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Carcinoma

A clinical trial to compare atezolizumab and cabozantinib with docetaxel in people with metastatic non-small cell lung cancer (after previous treatment with a checkpoint inhibitor and platinum-containing chemotherapy has not worked).

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Trial Status Active, not recruiting	Trial Runs In 15 Countries	Trial Identifier NCT04471428 GO41892
---	--------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04471428 GO41892
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No

How does the CONTACT-01 clinical trial work? This clinical trial is recruiting people who have a type of disease called non-small cell lung cancer, or NSCLC. In order to take part, patients must have NSCLC that has spread to other parts of the body (known as 'metastatic').

ForPatients

by Roche

The purpose of this clinical trial is to compare the effects, good or bad, of atezolizumab plus cabozantinib versus docetaxel alone on patients with metastatic NSCLC. In this clinical trial, you will get either atezolizumab plus cabozantinib or docetaxel alone.

How do I take part in this clinical trial? To be able to take part in this clinical trial, you must have previously received treatment for metastatic NSCLC with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.

You must not have previously received cabozantinib or docetaxel, or certain combinations of treatments. If your NSCLC shows certain genetic changes (called mutations), you may not be able to take part. You must not have any other significant health issues.

If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor. They will give you all the information you need to make your decision about taking part in the clinical trial. You can also find the clinical trial locations on this page.

You will have some further tests to make sure you will be able to take the treatments given in this clinical trial. Some of these tests or procedures may be part of your regular medical care. They may be done even if you do not take part in the clinical trial. If you have had some of the tests recently, they may not need to be done again.

Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial. You will also be told what other treatments are available so that you may decide if you still want to take part.

While taking part in the clinical trial, both men and women (if you are not currently pregnant but can become pregnant) will need to either not have heterosexual intercourse or take contraceptive medication for safety reasons.

What treatment will I be given if I join this clinical trial?

Everyone who joins this clinical trial will be split into 2 groups randomly (like flipping a coin) and given either:

- Atezolizumab, given through a drip as an infusion into the vein every 3 weeks, plus cabozantinib, given as a tablet to take every day
- OR docetaxel alone, given through a drip as an infusion into the vein every 3 weeks

You will have an equal chance of being placed in either group.

Although neither you nor your clinical trial doctor can choose which group you are in, you and your doctor will know which treatment(s) you are receiving.

How often will I be seen in follow-up appointments and for how long?

ForPatients

by Roche

You will be given the clinical trial treatment atezolizumab plus cabozantinib or docetaxel alone for as long as it can help you. You are free to stop this treatment at any time. You will be seen regularly by the clinical trial doctor every 3 weeks. These hospital visits will include checks to see how you are responding to the treatment and any side effects that you may be having. After being given your last dose, you will be contacted by the clinical trial staff approximately every 3 months, either in person or over the phone.

What happens if I am unable to take part in this clinical trial? If this clinical trial is not suitable for you, you will not be able to take part. Your doctor will suggest other clinical trials that you may be able to take part in or other treatments that you can be given. You will not lose access to any of your regular care.

For more information about this clinical trial see the **For Expert** tab on the specific ForPatient page or follow this link to ClinicalTrials.gov

Trial-identifier: NCT04471428